Member Info for Laura2022

Thanks both

How is posting 400 times and trashing me fair ?

Lets draw a line starting now

You've always appeared reasonable in the past..I've permanent binned the other 3 tho

I just don't get your obsessed nature

Take care

400 posts here and hardly any on CPX who can t file their accounts

You're obsessed

Review will consider a range of potential actions, including but not limited to a licensing or sale of Company assets - such as the EpiSwitch NST and EpiSwitch SCB tests - and a possible hive-off of the Company's US business into a separately funded entity.

You have to question their life choices

2mln volume nearly

LOTM

Yes, you were correct and I was wrong

I will assess today

Two tests now available commercially EpiSwitch CiRT addresses the clear need to help guide immuno-oncology treatments, accurately differentiating between non-responders and responders, and so avoiding unnecessary side-effects and costs. EpiSwitch PSE is, in our view, the commercially more relevant diagnostic that targets the large prostate cancer audience, improving identification of tumours, avoiding costly and invasive biopsies, and bringing precision to a currently uncertain diagnosis journey. Two additional tests, for colon cancer and canine cancers, are ready for partnering or out-licensing.

Modest share of such markets could be transformative Having successfully developed its lead products, management’s focus is on the execution of commercialisation plans, and securing the necessary funds to deliver on the potential of these tests. These are large markets and, despite the challenges in gaining clinical traction in such competitive segments, even a small share would be meaningful. Importantly, uptake in these indications would also highlight the advantages and benefits of EpiSwitch for development partnering.

We initiate with a valuation of £162m or 52p per share We value Oxford BioDynamics using a three-phase DCF based on peak future testing volumes. We initiate coverage with a valuation of £162/$203m, equivalent to 52p per share.

The bitter amd twisted who bought at 30p/40p+ can argue amongst themselves

Lets see what the week brings

I can see you also may hold revenue generating GUN and PXEN too

Wise

Wow porky

8hrs to government that reply

You did research but still bought a company valued at 1000 times its revenues

Your mistake

You've forgotten SCE are bust Aim123

Uncanny

You were suggesting the same when you did your last u turn

Yes Dug

Of course I'll do that...in the meantime have a think about why you bought OBD at £40mln market cap with no revenues

:))))))

PI

Not sure why the others don't just do the same or sell and move on

Maybe this latest media is...like the last few RNS...a prelude to the much needed fund raise .?

Have a nice evening gents

Maybe average down from 20p+??